Angiotech Pharmaceuticals nominates former Medtronic Vice Chairman Dr. Glen Nelson to Board of Directors
20 Mai 2004 - 3:01PM
PR Newswire (US)
Angiotech Pharmaceuticals nominates former Medtronic Vice Chairman
Dr. Glen Nelson to Board of Directors VANCOUVER, May 20
/PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:
ANPI; TSX: ANP), a specialty pharmaceutical company focusing on
drug-coated medical devices and biomaterials, today announced that
Dr. Glen D. Nelson, the former Vice Chairman of Medtronic has
accepted the Company's nomination for election as a director at its
upcoming general meeting. Dr. Nelson was Vice Chairman of
Minneapolis-based medical technology company Medtronic, Inc. from
1988 until his retirement in 2002. He currently serves on the Board
of Directors of The St. Paul Travelers Companies, Inc. Dr. Nelson
also holds the position of Emeritus Clinical Professor of Surgery
at the University of Minnesota and is a member of the Dean's
Council of Harvard University and The Johns Hopkins Medicine Board
of Visitors. "Dr. Nelson is well known in our industry for his
academic, clinical and business acumen," said William L. Hunter,
President and CEO of Angiotech. "We are honored that he has
accepted our nomination to the Board and shares our vision of
creating the next generation of drug-loaded devices and
biomaterials. His clinical practice and industry background will
provide our Board with a unique perspective, making him a valuable
asset to our company and shareholders." In 1980, Dr. Nelson joined
Medtronic as a director and was subsequently named Executive
Vice-President in 1986 and Vice-Chairman in 1988. Among his career
accomplishments, he was a practicing surgeon from 1969 until 1986,
specializing in vascular and bariatric surgery. For the latter
eleven years of that period, he also served as Chairman, President
and Chief Executive Officer of the Park Nicollet Medical Center, a
large multi-specialty group practice based in Minneapolis. He also
served as Chairman of the Board and Chief Executive Officer of
American MedCenters from 1984 through to 1986. Having earned a
bachelor of arts degree from Harvard College in 1959, Dr. Nelson
subsequently went on to complete his medical degree from the
University of Minnesota in 1963. He completed his training in
general surgery at Minneapolis-based Hennepin County General
Hospital in 1969 and was certified by the American Board of Surgery
one year later. The Company's Annual General and Extraordinary
Meeting of shareholders will be held in Vancouver at 9:00 a.m. on
Thursday, June 10, 2004. Information pertaining to the nomination
of Directors and other business matters has been mailed out as part
of the materials for the meeting. Vancouver-based Angiotech
Pharmaceuticals, Inc., a specialty pharmaceutical company focusing
on drug-coated medical devices and biomaterials, is dedicated to
enhancing the performance of medical devices and biomaterials
through the innovative uses of pharmacotherapeutics. To find out
more about Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI)(TSE:ANP),
please visit our website at http://www.angiotech.com/. Statements
contained herein that are not based on historical or current fact,
including without limitation statements containing the words
"anticipates," "believes," "may," "continue," "estimate,"
"expects," "may" and "will" and words of similar import, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Such factors include, among others, the following:
general economic and business conditions, both nationally and in
the regions in which the Company operates; technology changes;
competition; changes in business strategy or development plans; the
ability to attract and retain qualified personnel; existing
governmental regulations and changes in, or the failure to comply
with, governmental regulations; liability and other claims asserted
against the Company; and other factors referenced in the Company's
filings with the United States Securities and Exchange Commission
or the Canadian securities regulators. Given these uncertainties,
readers are cautioned not to place undue reliance on such
forward-looking statements. The Company does not assume the
obligation to update any forward-looking statements. DATASOURCE:
Angiotech Pharmaceuticals, Inc. CONTACT: Analysts: Rui Avelar,
Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext 6996;
Investors: Ian Harper, Angiotech Pharmaceuticals, Inc., (604)
221-7676 ext 6933; Media: Eric Starkman, Starkman & Associates,
(212) 252-8545 ext 12
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024